BioSpace News Archive

SURGE Therapeutics announced $26 million in Series A financing to address surgery-induced immune suppression and prevent post-surgical cancer recurrence and metastasis.

At the World Health Summit, the Bill & Melinda Gates Foundation announced it will commit $1.2 billion to support efforts to end all forms of polio globally.

Telix Pharmaceuticals Limited announces that the Chinese National Medical Products Administration Center for Drug Evaluation has approved an investigational new drug application to commence a pivotal Phase III registration study of TLX591-CDx, for the imaging of prostate cancer using Positron Emission Tomography that will bridge to the marketing authorisation granted to Illuccix® by the United States Food and Drug Administration.

Spectrum Dynamics Medical and Kromek Group plc announced the integration of Kromek CZT detectors in Spectrum digital SPECT/CT products, the VERITON-CT 400 series.

Innovent Biologics, Inc. announced that results of higher-dose cohorts in a phase 1b study of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese participants with overweight or obesity have been published online in eClinicalMedicine

Chinese Society of Clinical Oncology, an authoritative Chinese oncology institution, recently published the 2022 CSCO Guidelines on Diagnosis and Treatment of Cervical Cancer.

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 in China for the treatment of acne vulgaris on 14 October 2022.

At the European Association of Nuclear Medicine Annual Meeting, GE Healthcare proudly introduces Omni Legendi, the first system on its all-new, all-digital PET/CT platform.

NGM Biopharmaceuticals, Inc. will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration.

Acorda Therapeutics, Inc. announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC regarding licensing royalties relating to AMPYRA.